Metarafenib

美他非尼

Report date: 2022/07/19 16:22:54

NME

Base Information

Drug NameMetarafenib

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionVascular endothelial growth factor inhibitorsVascular endothelial growth factor receptor antagonistsTyrosine-protein kinase receptor RET inhibitors +[5]

TargetsVascular endothelial growth factorVascular endothelial growth factor receptorTyrosine-protein kinase receptor RET +[5]

Therapy Area/IndicationsSolid tumoursLiver Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesGuangzhou Nanxin Pharma Co Ltd

China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangzhou Nanxin Pharma Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursLiver Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A